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Purif ied protein derivative (PPD) skin tests often yield poor specif icity, so that
to develop new serological antigens for distinguishing between Mycobacterium tu-
berculosis infection and Bacille Calmette-Guerin (BCG) vaccination is a priority,
especially for developing countries like China. We predicted the antigenicity for
selected open reading frames (ORFs) based on the genome sequences of M. tu-
berculosis H37Rv and M. bovis BCG, as well as their functions and differences of
expression under different stimulus. The candidate ORFs were cloned from H37Rv
sequences and expressed as recombinant proteins in Escherichia coli. We studied
the serodiagnostic potential of 11 purif ied recombinants by using enzyme-linked
immunosorbent assay (ELISA) and involving a cohort composed of 58 TB patients
(34 males and 24 females), 8 healthy volunteers and 50 PPD-negative individuals
before and after BCG vaccination. For all the 11 antigens, the median OD val-
ues for the sera from TB patients were statistically signif icantly higher than those
for PPD-negative individuals before or after BCG vaccination (P<0.01). They
had at least 92% specif icity in healthy controls and six seroantigens (Rv0251c,
Rv1973, Rv2376c, Rv2537c, Rv2785c and Rv3873A) were never reported with
seroantigenicities previously. Thus the approach combining comparative genomics,
bioinformatics and ELISA techniques can be employed to identify new seroantigens
distinguishing M. tuberculosis infection from BCG vaccination.
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Introduction
Tuberculosis (TB) is an infectious bacterial disease
caused by Mycobacterium tuberculosis. Based on
surveillance and survey data, the World Health Or-
ganization (WHO) estimated that 9.27 million new
cases of TB occurred in 2007 globally (139 per 100,000
population). An estimated 1.32 million HIV-negative
people died from TB in 2007, and there were an addi-
tional 456,000 TB deaths among HIV-positive people
(1 ).
Currently, TB diagnosis largely depends on clin-
ical and radiographic (X-ray) examination validated
by sputum smear microscopy and bacterial culture.
Culture is not practical as a first-line defense due to
long cultivation period. Present confirmation of di-
agnosis relies on sputum smear examination, achiev-
ing a sensitivity ranging from 10% to 20%, and low
specificity. To make the diagnosis of TB more ac-
curate, fast and convenient, new diagnostic tech-
niques, including M. tuberculosis detection in clinical
specimens by PCR and immune reactions based on
cell-mediated-immune (CMI) or humoral immune re-
sponse, have been investigated. A serological test, un-
like the CMI-based diagnostic assays requiring living
cells, is an attractive diagnostic method for its con-
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venience, robustness and easy implementation in de-
veloping countries. However, no commercially avail-
able serological tool has so far shown sufficient sen-
sitivity and specificity to early detect M. tuberculo-
sis infection and differentiate infection from Bacille
Calmette-Guerin (BCG) vaccination (2 ). The reason
is generally believed to be the great heterogeneous an-
tibody response in TB patients (3 ). A necessary im-
provement in sensitivity can be achieved by combining
the best antigens, through the use of both cocktails
of single proteins and genetically engineered fusion
molecules containing several antigens (4 , 5 ).
In recent years, MTB48 (6 ), ESAT-6, CFP-10
(7 , 8 ) and other antigens were discovered by the tech-
niques in screening expression library of M. tubercu-
losis and by comparative genomics and proteomics
(9–12 ). Based on these observations, we hypothe-
sized that candidate antigens, with minimum similar-
ity to BCG or presumably drastically regulated un-
der different stimulus, may provide more specific tar-
gets to measure humoral immunity. We expressed 17
candidate antigens mainly based on M. tuberculosis
H37Rv sequence in Escherichia coli and serologically
evaluated 11 of them among TB patients and purified
protein derivative (PPD)-negative individuals before
and after BCG vaccination. Between the sera from
TB patients and PPD-negative individuals before or
after BCG vaccination, the levels of antibodies against
all the 11 assayed antigens were statistically different
(P<0.01). All the 11 assayed antigens had at least
92% specificity in healthy controls and six seroanti-
gens (Rv0251c, Rv1973, Rv2376c, Rv2537c, Rv2785c
and Rv3873A) were newly found.
Results
Selection of high antigenic proteins on
the basis of comparing proteins between
H37Rv and BCG P
The tBLASTn result showed that the identities of 174
genes between H37Rv and BCG P genomes were less
than 60%. Among them, 49 genes have signal pep-
tide or transmembrane structure and 55 are anno-
tated to MCE family or PE/PPE family, which is
supposed to play important roles in cell invasion or
immune responses (13–17 ). Therefore, we first se-
lected to clone and express 12 candidates belonging
to these two kinds of genes with high antigenic index
over 3.0 predicted by BEPITOPE software (Table 1).
Additionally, we also picked out 4 reportedly promis-
ing antigens, 2 heat shock proteins (HSPs) and 2 en-
zymes associated with metabolism to clone and ex-
press (Table 1). Based on the characteristic structure
and the predicted epitopes of the PPE proteins, we
dissected Rv3873 into the conserved N-terminal (PPE
region: Rv3873A) and the diverse C-terminal (MPTR
region: Rv3873B). In addition, we dissected Rv1563c
into Rv1563cA and Rv1563cB for the same reason.
Selection of H37Rv proteins recognized
serologically by sera of TB patients
In the total 22 proteins to be purified, 3 genes
(Rv1968, Rv1243c and Rv3590c) failed to be cloned
and 2 others (Rv1987 and Rv2875) failed to be pu-
rified. Finally, we successfully cloned and purified
17 H37Rv proteins (Table 2). The serological anti-
genicities of most of them have not been previously
identified by proteomic or genomic approaches. We
also included the PPD protein, because of its ho-
mologs among several other mycobacteria, to serologi-
cally evaluate its sensitivity and specificity among the
healthy, BCG-vaccinated and M. tuberculosis-infected
individuals.
During the first round of screening step, we at-
tempted to identify a broad panel of targets by us-
ing sera from 8 selected TB patients (including one
with kidney TB and another with liver TB) who all
had high titers of antibody against PPD from M. tu-
berculosis. The levels of specific antibodies in these
TB blood samples were compared with those in 8
healthy controls. Generally, the antibody responses
to the antigens could be grouped into three different
categories. The antibody levels in the sera of TB
patients were higher than those in healthy controls
for the proteins in category 1, contrast to those in
category 2, in which the antibody levels in the sera
from the patients were lower than those in healthy
controls. The proteins in category 3 were charac-
terized by low antibody responses to the sera from
patients as well as to healthy controls. Only anti-
gens in category 1 with marked difference (a mean
OD difference of more than 0.2) between the signal in
patients and controls were selected for further anal-
ysis (Table 2). Eleven antigens (Rv0251c, Rv1973,
Rv1984c, Rv2031c, Rv2185c, Rv2376c, Rv2537c,
Rv2785c, Rv2878c, Rv0934 and Rv3873A) satisfying
this criterion were selected. Among them, there is no
report for the serological antigenicities of Rv0251c,
Rv1973, Rv2376c, Rv2537c, Rv2785c and Rv3873A
proteins.
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Table 1 Assumed characteristics and identities of candidate antigens in H37Rv
Rv No. of gene Gene symbol*1 Identity (%) with Signal Transmembrane*3 Methods for
BCG P (tBLASTn)*2 peptide*3 detecting protein
Rv0251c hsp 100 − − in vivo (33 )
Rv0934 pstS1 99.47 + − Culture in vitro (34 )
Rv1243c*4 PE PGRS23 52.39 + − Computational prediction
Rv1563c*6 treY1 98.73 − − in vivo (35 )
Rv1966 mce3A 36 + + in vivo (36 )
Rv1968*4 mce3C 44 + + Computational prediction
Rv1971 mce3F 39 + + Computational prediction
Rv1973 possible mce 49 + + Computational prediction
Rv1984c cfp21 49.78 + − Culture in vitro (37 )
Rv1987*5 possible chitinase 37.74 + + Computational prediction
Rv2031c hspX 99.31 − − in vivo (20 )
Rv2185c TB16.3 99.31 − − Culture in vitro (38 )
Rv2376c cfp2 29.63 + − Culture in vitro (39 )
Rv2537c aroD 34.33 − + Computational prediction
Rv2785c rpsO 34.33 − − Computational prediction
Rv2875*5 mpt70 70.27 + − Culture in vitro (40 )
Rv2878c mpt53 100 + + Culture in vitro (41 )
Rv3590c*4 PE PGRS58 52 + − Computational prediction
Rv3804c fbpA 100 + + Culture in vitro (42 )
Rv3873*6 PPE68 45.65 + − in vivo (15 )
*1Annotations for gene symbols are shown according to the database in NCBI.
*2All BLAST reports were performed within local server, and all the reference sequences of proteins in H37Rv and the
sequence of BCG P genome were downloaded from NCBI; tBLASTn results were reported in September 2005.
*3The “+” and “−” marks in “Signal peptide” column represent the protein with and without signal peptide; the “+”
and “−” marks in “Transmembrane” column represent the protein with and without transmembrane structure.
*4The genes were not successfully cloned.
*5The recombinant proteins were not successfully purified.
*6The genes were dissected into two fragments to clone and express.
Establishment of the cutoffs and eval-
uation of the 11 serological antigens
with sera from TB patients and BCG-
vaccinated individuals
We evaluated 11 antigens and PPD with a panel of
blood samples collected from 50 TB patients (includ-
ing 6 extra pulmonary TB patients) and 50 PPD-
negative individuals before and after BCG vaccina-
tion. For all the 11 antigens and PPD, the median OD
values for the sera from TB patients were statistically
significantly higher than those for PPD-negative in-
dividuals before or after BCG vaccination (P<0.01).
For Rv1973, Rv2785c and PPD, the median OD val-
ues for the sera from PPD-negative individuals after
BCG vaccination were statistically higher than those
before BCG vaccination while, for Rv2185c, Rv2537c
and Rv0934, the median OD values for the sera from
PPD-negative individuals after BCG vaccination were
statistically lower than those before BCG vaccina-
tion (P<0.05) (data not shown). The cutoffs for
each antigen were established, and the sensitivity and
specificity for each individual antigen were calculated
(Table 3). The most frequently recognized antigens
were Rv1973 and Rv2031c, which were recognized by
38% of the sera from the TB patients tested, while
Rv1973 has a recognition frequency of 16% for BCG-
vaccinated population. All antigens had a specificity
of at least 92% for healthy controls.
Discussion
During recent years, antigens with performances sim-
ilar to or better than that of the Rv0934 (38 kDa)
protein have been identified (5 ). To identify ad-
ditional potentially promising serological antigens,
we combined comparative genomics, bioinformatics
and enzyme-linked immunosorbent assay (ELISA)
techniques to identify new seroantigens. Although we
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Table 2 Serological screening of 17 recombinant M. tuberculosis proteins
Protein Mean ODTB Mean ODHealth ΔOD value*
1 Selection*2 Reference
Rv0251c 0.963 0.519 0.444 + NR*3
Rv0934 1.006 0.774 0.232 + (5 )
Rv1563cA 0.172 0.129 0.043 − NR
Rv1563cB 0.274 0.309 −0.035 − NR
Rv1966 0.220 0.134 0.086 − NR
Rv1971 0.336 0.243 0.093 − NR
Rv1973 0.419 0.184 0.235 + NR
Rv1984c 0.493 0.275 0.218 + (5 )
Rv2031c 1.202 0.597 0.604 + (43 )
Rv2185c 1.119 0.644 0.475 + (5 )
Rv2376c 0.665 0.318 0.347 + NR
Rv2537c 0.645 0.417 0.228 + NR
Rv2785c 0.639 0.378 0.261 + NR
Rv2878c 0.636 0.399 0.237 + (44 )
Rv3804c 0.164 0.299 −0.135 − (45 )
Rv3873A 0.319 0.094 0.225 + NR
Rv3873B 0.215 0.163 0.052 − NR
PPD 0.974 0.204 0.770 + (2 )
*1The change in OD (ΔOD) value is calculated as the mean OD for the healthy control subtracted from the mean OD
for the TB patient. *2All antigens with ΔOD value >0.2 were selected (“+”). *3NR, not reported with seroantigenicity
previously.
Table 3 Sensitivities and specif icities of 11 recombinant proteins and PPD with sera from 50 TB
patients and 50 PPD-negative individuals before and after BCG-vaccination
Protein Cutoff*1 Sensitivity (%) Specificity (%)*2
TB patients BCG Controls
Rv0251c 0.239 34 4 2 98
Rv0934 0.185 26 4 2 98
Rv1973 0.445 38 16 8 92
Rv1984c 0.570 32 4 4 96
Rv2031c 0.071 38 6 0 100
Rv2185c 0.826 18 0 2 98
Rv2376c 0.563 24 4 6 94
Rv2537c 0.147 28 0 0 100
Rv2785c 0.270 16 2 0 100
Rv2878c 0.511 16 4 2 96
Rv3873A 0.492 24 6 2 98
Rv0934+Rv0251c 0.656 70 4 4 96
PPD 0.334 60 20 2 98
*1Cutoff = Mean ODHealth + 2.576×SD. *2Specificity = 100% − sensitivity (for the controls).
purified 17 recombinant proteins, we dropped out 6
proteins after the first round of evaluation and only
further evaluated other 11 with the sera from TB pa-
tients, healthy controls and BCG-vaccinated popula-
tions.
Six antigens (Rv0251c, Rv1973, Rv2376c,
Rv2537c, Rv2785c and Rv3873A) were novel in the
11 evaluated antigens. Among the 6 novel antigens,
Rv3873A and Rv1973 are worthy of noting. The 24%
sensitivity of Rv3873A showed that the PPE gene
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family can elicit strong humoral immune responses,
although it is generally believed that PE/PPE frag-
ment elicits T-cell immune responses in host organ-
isms (14–19 ). It is also interesting that the sensitiv-
ity of Rv1973 antigen in BCG-vaccinated populations
reaches 16% (the highest among the 11 evaluated
antigens) given that its identity between H37Rv and
BCG P is only 49.47%. We attributed its 16% sen-
sitivity to the polypeptide (ALLSYRPDTVQHDLE-
SARSRLTG) in the high antigenic index region, shar-
ing 60.9% identity with that (ALLSYSPDTLDQDFA-
TARSHLAG) in BCG P genome. Furthermore, from
the great difference of the sensitivities of Rv1973
and PPD between the healthy controls and BCG-
vaccinated individuals, we were tempted to imagine
that the new serological antigens may be discovered
to establish methods serologically monitoring the sta-
tus of BCG vaccination timely (20–22 ), which was
supposed to be extended to 10 to 15 years (23 ).
Six proteins have high predicted antigenicities but
showed no significant differences in sera between TB
patients and healthy controls. One reason may be
that these proteins, like the proven Rv3804c (antigen
85A) (24 , 25 ), mainly elicit cellular immunity instead
of humoral immunity. This is also the reason why
these proteins are worthy of assessing their abilities
to elicit cellular immunity. Another reason may be
the highly specific humoral immunological response
caused by its diversity (18 , 19 ), like PE/PPE protein
family. The C-terminals of PE/PPE proteins report-
edly mount on humoral immune response and their
sequences are highly diverse. During the infection
within the bodies of different individuals, the anti-
bodies may be produced to be mainly against the
different member of PE/PPE protein family. This
speculation is substantiated, in our later experiment,
with the 1.02 and 0.915 OD for the two sera recog-
nized by Rv3873B protein and 0.434 OD as its cutoff,
while its mean OD difference between TB patients
and healthy controls is only 0.052.
In our study, all the 11 antigens can statistically
differentiate TB patients from the BCG-vaccinated in
terms of the median OD values between the antibody
levels in the sampled sera. However, compared with
other studies, the 16% to 38% sensitivities of the pro-
teins in our study are lower. This may be resulted
from the following reasons. First, the same antigen
of different sources has different sensitivities in vari-
ous studies (23 , 26 , 27 ). For example, the sensitivity
of Rv0934, a well described lipoglycoprotein, ranges
from 16% to 94% in different papers. Furthermore,
the different post-translational modification between
recombinant proteins and native antigens extracted
from a M. tuberculosis complex may affect the hu-
moral immune response. Additionally, the various liv-
ing regions of the TB patients can also contribute to
the different sensitivity of the same antigen. It is well
known that China is an unevenly developing coun-
try with a large area, complex genetic background
and over 90% immunization rate of infants with BCG
from 1990 to 2006 (http://www.moh.gov.cn/open/
2007tjts/P49.htm). In this study, TB patients, BCG-
vaccinated individuals and healthy controls live in
many areas with different genetic background. The
impacts on sensitivity imposed by the genetic back-
ground and regions have been observed (28 , 29 ).
Even the same recombinant Rv0934 antigen showed
22% and 28% frequency recognition respectively when
tested with Danish TB patients and African popula-
tion. Besides, the immune response also reportedly
varied with the smear status and disease manifesta-
tion (30 , 31 ). So the different stage of disease on pa-
tients from high and low endemicity regions may also
be the reasons resulting in the different sensitivity of
the same antigen.
Considering the great heterogeneity from individ-
ual to individual and among various regions, we in-
creased the sensitivity with two-protein cocktail while
maintaining high specificity. One protein, genetically
fusing Rv0934 and Rv0251c together, has 70% sen-
sitivity and 96% specificity. Currently, more pro-
teins combined in various cocktail kits are under test
in order to find ideal kits with high sensitivity and
specificity.
Conclusion
By comparing the genome sequences of H37Rv and
BCG and predicting the antigenicities of the candi-
date genes, we systemically evaluated 11 purified anti-
gens with a cohort composed of 58 TB patients, 8
healthy volunteers and 50 PPD-negative individuals
before and after BCG vaccination. These 11 antigens
had at least 92% specificity in healthy controls and six
seroantigens (Rv0251c, Rv1973, Rv2376c, Rv2537c,
Rv2785c and Rv3873A) were novel. The approach in
this study combining comparative genomics, bioinfor-
matics and ELISA techniques will greatly facilitate
the identification of novel seroantigens distinguishing
M. tuberculosis infection from BCG vaccination.
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Materials and Methods
Sample population
Serum samples were collected from three different
groups of individuals recruited at the Second Hospi-
tal Affiliated to the General Hospital of the People’s
Liberation Army, China. The first group included
58 TB patients (34 males and 24 females) confirmed
with the following methods: X-ray, clinical symptoms
and patient history. Among the 58 TB patients, 8
had extrapulmonary TB and the other 50 had pul-
monary TB. The second group, which comprised 8
healthy volunteers with unknown exposure to TB,
confirmed by X-ray and/or clinical findings and pa-
tient history, was used as healthy controls in the first
round of screening step. They were not checked by
skin test with PPD. The third group consisted of 50
PPD-negative individuals checked by skin test. Af-
ter confirming their negative status, their sera were
collected as “before BCG vaccination” and then they
were BCG-vaccinated. The sera “after BCG vaccina-
tion” were collected three months after vaccination.
During the collection of serum, we fully adhered to
ethical requirements.
Antibody detection by ELISA
All samples with serum dilution of 1:50 were run in
duplicate. The ELISA procedure was performed as
follows: 96-well polystyrene microtiter plates were
coated for 2 h at 37◦C with 100 μL of antigen solu-
tion (1 μg/mL for single antigen and 10 μg/mL for
PPD) in phosphate-buffered saline (PBS, pH 7.4).
The coated plates were washed twice with PBS-T
(PBS, 0.05% Tween 20, pH 7.4), and blocked with
2% (weight/volume) bovine serum albumin (BSA) in
PBS-T overnight at 4◦C. In the next day, serum sam-
ples diluted 1:50 in PBS (pH 7.4) were applied and
incubated for 1 h at 37◦C. The plates were washed
three times with PBS-T and then incubated for 1 h
with rabbit anti-human IgG antibody conjugated with
horseradish peroxidase diluted 1:10,000 in PBS-T. Af-
ter 3 washings with PBS-T, the enzyme activity was
assayed by incubation for 15 min at 37◦C with 100
μL of mixtures of tetramethylbenzidine (TMB) (10
μg TMB) per well. 50 μL of 8 N sulfuric acid was
added to stop the reaction and the optical density
(OD) was measured at 405 nm.
Data analysis
The ELISA results were analyzed by using cutoff
values defined by the following equation: Cutoff =
ODmean + 2.576×SD, where ODmean and SD stand
for the mean OD value and standard deviation for the
healthy controls. If the mean OD value for any serum
of healthy control is greater than Cutoff, the cutoff
value will be recalculated in the above equation after
that OD reading is discarded. At the same time, we
considered the serum as positive. For statistical anal-
ysis, the difference between groups of TB patients
and BCG-vaccinated individuals or healthy controls
was calculated by the nonparametric Mann-Whitney
rank sum test, while the difference between BCG-
vaccinated individuals and healthy controls was calcu-
lated by Wilcoxon Signed Ranks Test, using the Sig-
maStat software package (SPSS Inc., Chicago, USA).
Differences were considered statistically significant if
the P value was below 0.05.
Comparing the identities of the proteins
encoded within the genomes of H37Rv
and BCG P
The reference sequences of all proteins in M. tubercu-
losis H37Rv were compared against those of the trans-
lated genomes of BCG P (M. bovis BCG strain Pas-
teur 1173P2) in local server with tBLASTn program.
All the reference sequences of proteins in H37Rv and
the sequence of BCG P genome were downloaded
from NCBI (http://www.ncbi.nlm.nih.gov/genomes).
Selecting and predicting the anti-
genecity of the primary candidate pro-
teins
Firstly, we picked out the proteins with low identity
(below 60%) between H37Rv and BCG P, which fell
into one of the following groups: (1) PE/PPE or MCE
protein family; (2) the assumable secreted or trans-
membrane proteins. Secondly, reportedly promising
antigens or proteins presumably being drastically reg-
ulated under different stimulus (such as HSPs) were
also selected. Finally, we cloned the candidate pro-
teins with the high antigenic index (above 3.0) pre-
dicted by BEPITOPE software (32 ) with the default
parameters.
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Cloning
Gene-specific primers and annealing temperatures
used for PCR and cloning were listed in Table S1.
PCR was conducted in a 50 μL mixture with 0.25 μL
PyroBest DNA polymerase (Takara, Japan), 10 ng of
H37Rv genome DNA, 0.4 μM primers, and 250 μM
dNTPs. PCR was initiated by a denaturation step
at 94◦C for 5 min, followed by 25 cycles of denat-
uration (94◦C, 30 s), annealing (temperatures listed
in Table S1, 30 s), extension (72◦C, 2 min), and a
final extension step (72◦C, 10 min). The PCR prod-
ucts were cloned into pET28b+ bacterial expression
plasmid (Novagen, Germany) at the restriction sites
(Table S1). All DNA segments synthesized by PCR
were verified by sequencing.
Expression and purification of recombi-
nant proteins
E. coli strain BL21-Gold (DE3) (Stratagene, USA)
was used as the cloning host and for the overex-
pression of all recombinant proteins except Rv1984c,
Rv2537c and Rv2785c proteins, which were expressed
in E. coli strain Rosetta (DE3) (Novagen). Expres-
sion was induced with 1 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG) for 3–5 h at 37◦C. Bacte-
rial pellets were harvested by centrifugation at 6,000
rpm and 4◦C for 10 min, washed in Wash Buffer (20
mM Tris-HCl, 0.5 M NaCl, pH 8.0). Pellets were
thawed and resuspended in Buffer A (20 mM Tris-
HCl, 0.5 M NaCl, 5 mM imidazole, pH 8.0), and lysed
using a JY92-II Ultrasonic Crasher (Ningbo Scientz
Biotechnology Co. Ltd., China) with 60 rounds of
5-second sonication/10-second ice incubation. All the
following centrifugation procedures were performed at
12,000 rpm and 4◦C for 20 min.
Soluble Rv0251c, Rv2031c, Rv2185c and Rv2376c
proteins were purified in the following way: E. coli
cells overexpressing recombinant proteins were lysed
by sonication in Buffer A. The supernatants from the
mixtures were loaded on a Ni-NTA column and the
bound proteins were eluted stepwise with Buffer A
containing from 5 to 300 mM imidazole.
The rest recombinant proteins Rv1971, Rv1973,
Rv2537c, Rv2785c, Rv2878c, Rv1563cB, Rv3873B,
Rv3804c, Rv1984c, Rv0934, Rv1563cA, Rv1966 and
Rv3873A were purified as follows: E. coli cells with
high levels of recombinant proteins were sonicated in
Wash Buffer. The lysates were centrifuged and the
supernatants were decanted. The left pellets were re-
suspended with Buffer B (50 mM Tris-HCl, 5% Tri-
ton X-100, 50 mM NaCl, 5 mM EDTA, pH 8.0) and
centrifuged, repeated for twice. The washed pellets
(inclusion body) were lysed in Buffer C (20 mM Tris-
HCl, 0.5 M NaCl, 8 M Urea, pH 8.0) and centrifuged.
The supernatants from mixtures were loaded on a Ni-
NTA column (Qiagen, Germany), and the bound pro-
teins were eluted stepwise with Buffer C containing
from 5 to 200 mM imidazole.
The concentrations of all proteins were determined
by the protein A280 method of ND-1000 Spectropho-
tometer (NanoDrop Technologies, USA).
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